Covid-19 Impact on Neurological Biomarkers Market Size, Share, Trends and Forecast 2021-2026: Abbott, QIAGEN, Thermo Fisher Scientific – KSU | The…

Neurological Biomarkers Market Report recently published by Worldwide Market Reports company focuses mostly on required solutions to the users. The study includes analysis, forecast, and revenue from 2021 to 2026. The advancement rate is evaluated dependent on insightful examination that gives credible information on the worldwide market. Imperatives and advancement points are merged together after a significant comprehension of the improvement of this market.

There is Continuous growth in the Neurological Biomarkers Market in the last five years and also continued for the forecasted period. Neurological Biomarkers industry report analyses the outline of the global market with respect to major regions and segmented by types and applications. This report covers top manufacturers, product scope, market overview, market opportunities, market risk, market driving force, technological advancement, distributors, traders, dealers, research findings.

RequestMore Detailed Information About Industry: Get Sample Report Click Here!

The top players covered in Neurological Biomarkers Market are: Abbott, QIAGEN, Thermo Fisher Scientific, Athena Diagnostics, Bio-Rad Laboratories

The point-to-point elucidation of the markets assembling system, the usage of advancement, conclusions of the world market players, dealers and suppliers order, and the explicit business data and their improvement plans would help our customers for future courses of action and movement planned to make due in the Neurological Biomarkers market.

The data always remains relevant to the market and consists of market dynamics, prospects, starts, market dynamics, and even the Global market volumes into account. It filled with data and deep analysis on market value, environmental analysis, Neurological Biomarkers advanced techniques, latest developments, Neurological Biomarkers business strategies, and current trends. Hence, it becomes a valuable asset to both manufacturers and investors of the industry.

Points Covered of this Neurological Biomarkers Market report are:

The international Neurological Biomarkers market has been characterized by several primary factors, with each factor tends to play a crucial role in the boom of the market. The growth in the products has doubled with the smoother availability of the customer base that has been helping the company flourishing globally. On the other hand, the presence of a dynamic supply chain has helped the company to grow exponentially.

The analysis and forecast of the global market of Neurological Biomarkers have no longer been, specifically, analyzed that are not only on a global foundation but additionally on a neighborhood foundation. When a better look taken at the areas, the market has concentrated, and the file interior the important makes a strong point of Europe, Middle East & Africa, Asia Pacific, Latin America, and North America. These areas have studied regarding the hooked-up traits and the diverse possibilities in addition to the outlook that allows inside the benefitting of the market ultimately.

Request Discount for this Research:(Click Here!)

Research Methodology:

The Neurological Biomarkers market report has been prepared after thorough market research being conducted. It has been prepared as per Porters Five Force Model. In terms of timeline, the market takes the period between 2021-2026 into account for assessment. Apart from this, a comprehensive SWOT analysis has been provided for swift business decision making.

Enumerating some of the fundamental parameters encompassed in the report:

Global Neurological Biomarkers Market Report includes Detailed TOC points:

Customization Service of the Report: (Place Query: Click Here!)

Worldwide Market Reports provides customization of reports as per your request. This report can be personalized to meet your requirements. Get in touch with our research team, who will make sure you get a report that suits your necessities.

Contact Us:Mr. ShahWorldwide Market Reports,Tel: U.S. +1-415-871-0703 / U.K. +44-203-289-4040 / Japan +81-50-5539-1737Email: sales@worldwidemarketreports.com

See the original post:
Covid-19 Impact on Neurological Biomarkers Market Size, Share, Trends and Forecast 2021-2026: Abbott, QIAGEN, Thermo Fisher Scientific - KSU | The...

Interventional Neurology Devices Market Size By Analysis, Key Vendors, Regions, Type and Application, and Forecasts to 2027 – NeighborWebSJ

Fort Collins, Colorado: Reports Globe has published the latest study on Interventional Neurology Devices Market Report Analysis by Size with Future Outlook, Key Players SWOT Analysis and Forecast to 2026. It uses exploratory techniques such as qualitative and quantitative analysis to identify and present data on the target market. Successful sales strategies have been mentioned that will help you do business in record time and multiply customers.

This report is presented clearly and concisely to help you better understand the structure and dynamics of the market. The trends and recent developments in the Interventional Neurology Devices market were analyzed. The opportunities that lead to the growth of the market were analyzed and presented. Focusing on the global market, the report provides answers to the key questions stakeholders are facing today around the world. Information on market size raises the problem of increasing competitiveness and hampering market-leading sectors and market growth.

Get Exclusive Sample of Report on Interventional Neurology Devices market is available @ https://reportsglobe.com/download-sample/?rid=126683

Some of the Important and Key Players of the Global Interventional Neurology Devices Market:

Interventional Neurology Devices market research report provides detailed information on the following aspects: Industry Size, Market Share, Growth, Segmentation, Manufacturers and Advancement, Key Trends, Market Drivers, Challenges, Standardization, Deployment Models, Opportunities, Strategies, Future Roadmaps and Annual Forecasts to 2027, etc. The report will help you also in understanding the dynamic structure of the Interventional Neurology Devices market by identifying and analyzing market segments. The Global Interventional Neurology Devices 2021 Industry Research Report has given the expected compound annual growth rate (CAGR) as a% of value for a given period of time and clearly helps the user make their decision based on the futuristic chart of the key players on the global Interventional Neurology Devices market. The report introduces some of the major players in the global Interventional Neurology Devices market and offers insightful information about the Interventional Neurology Devices industry such as Business Overview, Interventional Neurology Devices Market Product Segmentation, Revenue Segmentation, and the Latest Information. Developments.

Additionally, the Interventional Neurology Devices market report includes a comprehensive strategic review as well as summarized studies of the growth, key factors, and market opportunity by which to evaluate the Interventional Neurology Devices market and other important market related details on Interventional Neurology Devices. The investigation of the research report also helps uncover accurate industry statistics depicting the ultimate model of the global Interventional Neurology Devices market, including various types, applications, market growth structures, and opportunities. In addition, the study of the market research report provides an investigation and analysis of the past and current performance of the regional market that includes regions by department and subdivision. This regional analysis studies various key market parameters such as Interventional Neurology Devices market growth rate in each region, production volume and capacity, market demand and supply, and return on investment (RoI).

Request a Discount on the report @ https://reportsglobe.com/ask-for-discount/?rid=126683

Some of the key questions answered in the report include-

1. What is the overall structure of the market?2. What was the historical value and what is the forecasted value of the market?3. What are the key product level trends in the market?4. What are the market level trends in the market?5. Which of the market players are leading and what are their key differential strategies to retain their stronghold?6. Which are the most lucrative regions in the market space?

Browse the complete report @ https://reportsglobe.com/product/global-interventional-neurology-devices-market-insight/

Global Interventional Neurology Devices market is segmented based by type, application and region.

Interventional Neurology Devices Market Segmentation, By Type

Interventional Neurology Devices Market Segmentation, By Application

The prime objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing. Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

Global Interventional Neurology Devicesmarket Key Report Highlights:

This in-depth research documentation offers an illustrative overview of the entire market outlook with details on scope, executive summary, and market segments The report also includes sections on the competitive spectrum, highlighting major players, with a detailed assessment of supply chain management, competition dynamics, and growth objectives. Other crucial details on Porters Five Forces assessment, SWOT analysis, and data triangulation methods have also been included in the report. Other relevant details on production patterns, growth rate, market share of each of the segments have also been pinned in the report. The report also houses crucial analytical details on revenue share and sales projections, besides volumetric estimations of each of the product segments have also been highlighted in the report to encourage unfaltering market decisions and sustainable revenue streams in the global Interventional Neurology Devices market.A dedicated chapter on COVID-19 analysis has therefore been included in this versatile report to encourage future-ready business discretion aligning with post-COVID-19 market environment.

Major Points from Table of Content:

1. Executive Summary2. Assumptions and Acronyms Used3. Research Methodology4. Interventional Neurology Devices Market Overview5. Interventional Neurology Devices Supply Chain Analysis6. Interventional Neurology Devices Pricing Analysis7. Global Interventional Neurology Devices Market Analysis and Forecast by Type8. Global Interventional Neurology Devices Market Analysis and Forecast by Application9. Global Interventional Neurology Devices Market Analysis and Forecast by Sales Channel10. Global Interventional Neurology Devices Market Analysis and Forecast by Region11. North America Interventional Neurology Devices Market Analysis and Forecast12. Latin America Interventional Neurology Devices Market Analysis and Forecast13. Europe Interventional Neurology Devices Market Analysis and Forecast14. Asia Pacific Interventional Neurology Devices Market Analysis and Forecast15. Middle East & Africa Interventional Neurology Devices Market Analysis and Forecast16. Competition Landscape

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://reportsglobe.com/need-customization/?rid=126683

How Reports Globe is different than other Market Research Providers:

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email: [emailprotected]

Web: reportsglobe.com

Read more:
Interventional Neurology Devices Market Size By Analysis, Key Vendors, Regions, Type and Application, and Forecasts to 2027 - NeighborWebSJ

Patrick Mahomes in NFL concussion protocol: What needs to happen for Chiefs star to play against Bills – ESPN

Kansas City Chiefs quarterback Patrick Mahomes is in the NFL's concussion protocol, and that's really all we can say about his status six days before the AFC Championship Game.

We don't know how long he will be sidelined. We don't know if he will be able to play Sunday. We don't even know for sure if he suffered a concussion.

What we do know is that brain health was one of the major storylines of the NFL's divisional playoff round. Mahomes was removed from the Chiefs' victory over the Cleveland Browns on Sunday after a hit at the end of a run left him staggering. A day earlier, Baltimore Ravens quarterback Lamar Jackson was ruled out of a loss to the Buffalo Bills after his head slammed to the ground.

What's in store for Mahomes this week? Let's take a closer look.

First off, we don't know one way or the other what Mahomes was diagnosed with. And importantly, it's not required for a player to have been immediately diagnosed with a concussion in order to be put in the protocol. All the Chiefs have confirmed is that he's in the protocol. On Monday, coach Andy Reid stopped short of saying that Mahomes had suffered a concussion.

In 2018, the NFL adjusted its protocol to require in-game evaluations for "all players demonstrating gross motor instability (e.g., stumbling or falling to the ground when trying to stand) to determine the cause of the instability." That roughly fits what happened Sunday to Mahomes. The protocol goes on to say that if a doctor "determines the instability to be neurologically caused, the player is designated a 'No-Go' and may not return to play."

2 Related

This change was in response to the scary injury suffered in Dec. 2017 by Houston Texans quarterback Tom Savage, who could be seen shaking on the ground after a hit but was allowed to remain in the game. He was later ruled out and diagnosed with a concussion. That adjustment allowed doctors to rule players out of games after examining them for these symptoms.

Mahomes, in fact, was ruled out even though he was running in the stadium tunnel after the injury, Reid said.

Of course. But whether he did or didn't, he must pass through the same five-step process to be cleared for a return.

The first thing you should know is that prior to the season, every NFL player takes neurological and balancing tests when in a noninjured state to provide a "normal" score. Those results can later be used to help diagnose a concussion, and to determine when a player's neurological activity and balance has returned to its previous state following a brain injury. The five steps are:

Step 1: Based on symptoms, the player can engage in light stretching, balance training and eventually progress to light aerobic exercise.

Step 2: The player can graduate toward cardiovascular exercise and dynamic stretching, and then take neurological and balance tests. He can pass through this step once those test results match his baseline scores.

Step 3: The player can move toward a limited amount of football-specific exercise. That includes up to 30 minutes of practice time, under the supervision of an athletic trainer.

Step 4: Football activities can increase to noncontact drills such as throwing and running. Another set of tests must again show baseline results.

Step 5: This requires the team doctor to clear the player for contact. Once that happens, the player must be examined by an independent neurological consultant (INC). If the "INC" affirms the team doctor's decision, the player is cleared to practice full and play in the team's next game.

The protocols intentionally carry no time requirements. They do not require a player to sit out a game, largely because the science of concussions show that brain injuries heal at unpredictable rates. Players could conceivably return to baseline quickly, without missing a game, or they could miss multiple games or even the remainder of a season.

1:26

Adam Schefter breaks down the concussion protocols Patrick Mahomes must clear to be eligible to play in the AFC title game vs. the Bills.

That's not entirely true. According to the NFL, using data from the 2015-19 seasons, the median length of time for quarterbacks to emerge from the concussion protocol is seven days.

It is and they do, but the NFL built this protocol to ensure that doesn't happen with brain and neurological injuries. By requiring a return to baseline test results, the NFL's implicit policy is that a player with a brain or neurological injury can't return until he is fully healed. Football contact after only a partial recovery can exacerbate the injury.

Mahomes isn't supposed to be able to "will" himself back on the field or "suck it up." And the Chiefs aren't supposed to even have the opportunity to take the kind of calculated risk they do when they allow a player back on the field when he has, say, a mildly sprained knee.

The biggest distinction of the concussion protocol is that it requires an independent doctor to confirm the return. That doctor is not affiliated with the team or player but has been approved jointly by the league and the NFL Players Association. The final step of getting clearance from the independent doctor is intended as a failsafe for either the player or the team acting too aggressively.

Conference championship previews Schedule, brackets, TV times

On Monday, Reid told reporters: "There was a chance back in the day that Patrick comes back in [the game]. You saw him run up the tunnel. By the time he got to that point he was feeling pretty good. But there's a certain protocol you have to follow and that takes it out of the trainer's hand and the player's hand and the doctor's hand."

This will be a story for the entire week. It's possible we'll find out when (and if) Mahomes has moved on to Step 3, based on the Chiefs' injury participation report for practice. Otherwise, it's possible we won't know if Mahomes will be able to play until the weekend. The Bills-Chiefs game will kick off at 6:40 p.m. ET on Sunday.

Mahomes himself has suffered one reported concussion in his career, during the 2014 college season at Texas Tech. He returned to play in the team's next game, which was two weeks later because of a scheduled bye.

Go here to see the original:
Patrick Mahomes in NFL concussion protocol: What needs to happen for Chiefs star to play against Bills - ESPN

Cell and Gene Therapies Shatter Prior Records, with Continued Growth Expected – BioSpace

Cell and gene therapies achieved record growth in 2020, surpassing prior high points in terms of financings and approvals. Janet Lambert, CEO of the Alliance for Regenerative Medicine (ARM), painted a rosy picture despite a few challenges at the 2021 Cell & Gene State of the Industry Briefing during this years Biotech Showcase, held virtually January 11-15.

2020 was a record-shattering year for financing, with $19.9 billion raised in 2020, up from the $9.8 billion raised in 2019 and the $13.3 billion raised in 2018 the previous record, she said.

Follow-on financings, at $6.8 billion, accounted for the largest portion of funding, followed by venture capital at $5.6 billion and IPOs at $3.7 billion. Upfront payments from partnerships totaled $3 billion and private placements totaled $1.2 billion.

The number of large financings exceeding $200 million grew noticeably. Sana Bios $700 million private financing, announced last June, topped the field. Iovance and bluebird bio gained the most from follow-on financing, with fundings of $604 million and $575 million, respectively. Legend Bio led the list of IPOs, raising $487 million last May.

Large pharma continued to buy-in to biotechs for research, development, commercialization, and licensing agreements focuses largely on oncology and CNS disorders, Lambert said. She cited Sangamo, with two major collaborations with Biogen ($350 million) and Novartis ($75 million), though adding, Bayer is especially active.

In the stock market, Regenerative medicine companies outperformed the NASDAQ Biotech Index, she continued. Although stock prices for virtually everything plummeted in mid-March, biotech stocks rebounded. Cell based immuno-oncology (IO) share prices increased 80% from their January 1 levels. Gene therapy was close behind, with a 70% increase, and all publicly traded regenerative medicine companies saw a 50% increase.

Given the overall environment, it seems safe to predict that 2021 will be another good year for regenerative therapies.

Currently, there are approximately 1,100 gene, cell and tissue-based therapeutic developers throughout the world. Of those, the overwhelming majority are in North America, with 543. We saw a lot of growth in China, Japan, and Korea, she said, with 295 companies. Europe boasts 209.

Globally, 1,220 clinical trials are underway for regenerative medicine.

More than 100 clinical trials commended in the fourth quarter alone, Lambert said. Roughly, they are divided evenly among cell, gene, and IO. With 152 trials in phase III and nearly half of those in gene therapy, this offers strong support for predictions by both the FDA and EMA that there will be 10 to 20 advanced therapies approved each year through 2025.

What people often forget, Lambert said, quoting Amy Price, a mother of two gene therapy recipients, is that cell and gene therapies arent some fantastical futuristic thing. Two of the Price children received gene therapy in a clinical trial 10 years ago for metachromatic leukodystrophy (MLD), a historically fatal disease. That drug, Libmeldy, by Orchard Therapeutics, was approved in Europe in 2020, making it one of the most significant milestones of the year.

The benefits of cell and gene therapy have expanded beyond experimental treatments.

Patients are continuing to benefit from innovative therapies, Lambert said. We saw a significant number of gene therapy approvals in 2020. In addition to Libmeldy, she cited approvals of Zolgensma (by Novartis Gene Therapies) in Europe, Japan, and Canada; Tecartus (by Kite, a Gilead company) in the U.S.; and Luxturna (by Spark/Roche) in Canada.

Looking forward, oncology, and particularly IO, dominates the regenerative medicine landscape. Some 554 oncology trials are underway.

Investors have invested heavily in this space for some time, and IO comprises 50% of Phase I trials in cell and gene therapy, Lambert noted. Focus is increasing on allogeneic therapies as well as gene editing.

Central nervous system therapeutics are the second most popular therapeutic indication for regenerative therapies for the second year in a row, with 94 trials. 2020 saw promising data from the first-ever attempt iPSC therapy for Parkinsons disease.

Gene editing continues to advance in the clinic, she added. For the first time, a patient was treated with CRISPR therapy in vivo and, later, systemically with CRISPR. CRISPR Therapeutics and Vertex Pharmaceuticals shared data (during J.P. Morgan week) from a sickle cell trial of 20 patients.

Despite these scientific advances and investor enthusiasm, cell and gene therapies face challenges in terms of dosing and delivery, and chemistry, manufacturing and controls (CMC), Lambert admitted. Gene therapy represents almost half of the Phase III pipeline, so we expect to learn a lot quite soon.

While it goes without saying that 2020 was a challenging year, many of the repercussions of the COVID-19-related disruptions remain to be seen. They extend not only to operational and clinical disruptions but also to regulatory backlogs and the politicization of diagnostics and therapeutics, all set against the usual challenges of fast-moving science.

None-the-less, Lambert pointed out, There were some positive developments.

As she said, Medicare approved a new diagnosis related group (DRG) for CAR T cell therapy and promulgated a new rule for outcomes-based therapies, thus enabling a new payment model that ARM deems essential for cell and gene therapies. In Europe, the European Commissions pharmaceutical strategy now recognizes the importance of cell and gene therapy. We are encouraged that we can build on that starting point with the Commission, Lambert said. ARM also is expecting progress on n-of-one therapies for ultra-orphan indications this year.

Looking ahead to 2021, Lambert identified six regenerative therapies on the FDAs docket from Mallinckrodt, bluebird, BMS, PTC Bio, and Gensight Bio. All indications are that 2021 will be a fantastic year of scientific, technological, and clinical progress in this sector, Lambert predicted.

See the rest here:
Cell and Gene Therapies Shatter Prior Records, with Continued Growth Expected - BioSpace

Sarepta Therapeutics and Genevant Sciences Announce Research Collaboration for Lipid Nanoparticle-Based Gene Editing Therapeutics – GlobeNewswire

-- Alliance will assess the use of Sareptas proprietary gene editing technology and Genevants proprietary LNP delivery platform for multiple neuromuscular targets --

-- Sarepta to have options for an exclusive license to Genevants LNP technology for four neuromuscular indications --

-- Genevant may receive approximately $50 million in near-term payments and is also eligible for significant future milestones and royalties --

CAMBRIDGE, Mass., VANCOUVER, British Columbia, and BASEL, Switzerland, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, and Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and the industrys most robust and expansive lipid nanoparticle (LNP) patent estate,today announced a research collaboration and option agreement for the delivery of LNP-gene editing therapeutics in Sareptas pipeline for neuromuscular diseases. LNPs offer the potential for a non-viral approach to gene editing and can provide both optimal uptake into desired cells and efficient release, resulting in functional delivery of gene editing cargo, such as CRISPR-Cas, to target tissues.

Gene editing has the potential to revolutionize the treatment of diseases caused by genetic mutations - including rare neuromuscular diseases - by permanently altering genes that lead to disease. Sarepta is pursuing a variety of approaches to genetic medicine including exon skipping, gene therapies and gene editing in pursuit of cures for rare diseases.

Under the terms of the agreement, Genevant will design and collaborate with Sarepta in the development of muscle targeted LNPs to be applied to gene editing targets in early stage development. Sarepta will have rights to an exclusive license to Genevants LNP technology for up to four neuromuscular indications, including Duchenne muscular dystrophy. Genevant may receive approximately $50 million in near-term payments and is also eligible for significant future development, regulatory and commercial milestones and tiered royalties ranging from the mid-single to low-double digits on future product sales.

As Sarepta works to advance precision genetic medicine across multiple modalities, weve invested in partnering and research efforts focused on improving the utility and benefit of gene-based medicines and providing the greatest possible outcome to patients. This includes advancing our pre-clinical gene editing program, looking at both viral and non-viral methods to produce a functional gene in order to treat a broad range of neuromuscular diseases, said Doug Ingram, president and chief executive officer, Sarepta Therapeutics.Genevants established leadership and proven LNP technology offers the potential to deliver gene editing machinery to targeted tissue through a non-viral delivery approach. Applying this science to neuromuscular diseases fits squarely within our mission to translate scientific breakthroughs into meaningful advances for patients whose lives have been impacted by rare disease.

Genevant scientists have been at the forefront of LNP delivery of nucleic acids for over 20 years. Our platform is the most clinically validated in the space and is the delivery technology behind the first nucleic acid-LNP product to have achieved FDA approval, said Pete Lutwyche, Ph.D., president and chief executive officer, Genevant Sciences Corporation. Efficient, optimized delivery is often the difference between successful and unsuccessful nucleic acid drug development, and we are excited to bring our experience to Sareptas gene editing programs in neuromuscular disease where new options and new approaches are desperately needed.

About Genevant SciencesGenevant Sciences is a leading nucleic acid delivery company with world-class platforms, the industrys most robust and expansive lipid nanoparticle (LNP) patent estate, and decades of experience and expertise in nucleic acid drug delivery and development. The Companys scientists have pioneered LNP delivery of nucleic acids for over 20 years, and the Companys LNP platform, which has been studied across more than a dozen discrete product candidates and is the delivery technology behind the first and only approved RNAi-LNP (patisiran), enables a wide array of RNA-based applications, including vaccines, therapeutic protein production, and gene editing. Genevant Sciences is committed to transforming the future of human health. For more information, please visitwww.genevant.com.

AboutSarepta TherapeuticsAt Sarepta, we are leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with rare disease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Companys programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. For more information, please visitwww.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.

Forward-Looking StatementsThis press release contains "forward-looking statements." Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements regarding the parties obligations and responsibilities under the agreement, potential payments and fees and Sareptas right to an exclusive license to Genevants LNP technology for up to four neuromuscular indications; the potential benefits of LNPs, including offering a non-viral approach to gene editing that can provide both optimal uptake into desired cells and efficient release, resulting in functional delivery of gene editing cargo, such as CRISPR-Cas, to target tissues; the potential for gene editing to revolutionize the treatment of diseases caused by genetic mutations including rare neuromuscular diseases by permanently altering genes that lead to disease; the goal of Genevant to design and collaborate with Sarepta in the development of muscle-targeted LNPs that can be applied to gene editing targets in early stage development; and Sareptas goal to advance its pre-clinical gene editing program, looking at both viral and non-viral methods to produce a functional gene in order to treat a broad range of neuromuscular diseases.

These forward-looking statements involve risks and uncertainties, many of which are beyond Sareptas control. Known risk factors include, among others: the expected benefits and opportunities related to the collaboration between Sarepta and Genevant may not be realized or may take longer to realize than expected due to challenges and uncertainties inherent in product research and development. In particular, the collaboration may not result in the discovery of any new therapeutic compounds or any viable treatments suitable for commercialization due to a variety of reasons, including any inability of the parties to perform their commitments and obligations under the agreement; Sarepta may not be able to execute on its business plans and goals, including meeting its expected or planned regulatory milestones and timelines, clinical development plans, and bringing its product candidates to market, due to a variety of reasons, many of which may be outside of Sareptas control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover Sareptas product candidates and the COVID-19 pandemic; and those risks identified under the heading Risk Factors in Sareptas most recent Annual Report on Form 10-K for the year ended December 31, 2019, and most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by Sarepta which you are encouraged to review.

Any of the foregoing risks could materially and adversely affect Sareptas business, results of operations and the trading price of Sareptas common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.

Internet Posting of Information by Sarepta

We routinely post information that may be important to investors in the 'For Investors' section of our website atwww.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Source: Sarepta Therapeutics, Inc.

Contacts:

Sarepta Therapeutics, Inc.Investors: Ian Estepan, 617-274-4052, iestepan@sarepta.comMedia: Tracy Sorrentino, 617-301-8566, tsorrentino@sarepta.com

Genevant SciencesPete Zorn, pete.zorn@genevant.com

Excerpt from:
Sarepta Therapeutics and Genevant Sciences Announce Research Collaboration for Lipid Nanoparticle-Based Gene Editing Therapeutics - GlobeNewswire

Ixaka (formerly Rexgenero) Launches as an Integrated Cell and Gene Therapy Company – Business Wire

LONDON--(BUSINESS WIRE)--Ixaka Ltd, an integrated cell and gene therapy company focused on the natural power of the body to cure disease, launches today. The Companys shareholders have funded the business with over 40 million in financing.

Previously Rexgenero Ltd, a UK-based company pioneering the development of cell therapies to treat serious diseases such as cancer and chronic limb-threatening ischaemia (CLTI), the launch of Ixaka follows integration of its nanoparticle gene therapy business in France and a shareholder restructuring.

The new business will continue to develop Ixakas proprietary technologies concentrated multi-cell therapies (MCTs) and targeted nanoparticle (TNP) therapeutics. Ixakas technologies enhance the naturally therapeutic power of cells by targeting curative cells at the site of disease, or by directly modifying cells within the body to improve disease targeting and boost their restorative function.

Joe Dupere, CEO of Ixaka, commented: Ixakas broad offering of integrated cell and gene therapy capabilities, encompassing cell-based products and an innovative in vivo gene delivery platform, provides a strong foundation for our ambitions to become a leader in cell and gene therapies. Our focus is now on accelerating progress to help realise the potential for durable and curative cell and gene therapies. By exploring multiple therapies across oncology and cardiovascular, genetic, neurological and autoimmune diseases, we are well positioned to bring life-changing treatments to multiple patient populations with critical unmet needs.

REX-001, Ixakas lead MCT product, is an autologous cell-based product in clinical development for the treatment of CLTI. REX-001 is currently being evaluated in the pivotal Phase III SALAMANDER clinical trial at multiple sites across Europe.

Ixakas polymeric nanoparticle platform can be used to perform genetic modifications directly inside a patients body. The platform enables in vivo targeting and transduction of T cells, and is currently being applied to generate chimeric antigen receptor (CAR) T-cell therapies in vivo for haematological malignancies. Modifications of the components will allow the technology to target a broad range of serious diseases, including cancers and genetic, neurological and autoimmune diseases.

A total of $15.4 billion was raised in the first half of 2020 for the development of cell and gene therapies, with 1,078 regenerative medicine and advanced therapy clinical trials ongoing worldwide1.

References1. https://alliancerm.org/sector-report/h1-2020-report/

ENDS

About Ixaka

Ixaka is a cell and gene therapy company focused on using the natural powers of the body to cure disease.

Ixakas proprietary technologies enhance the naturally therapeutic power of cells by increasing the presence of curative cells at the site of disease, or by directly modifying cells within the body to improve disease targeting and boost their restorative effect.

Ixakas technologies concentrated multi-cell therapies and nanoparticle therapeutics demonstrate potential for the treatment of a broad range of serious diseases across oncology, cardiovascular, neurological and ocular diseases, and genetic disorders.

Ixaka has offices in London, UK with R&D and manufacturing operations in Seville, Spain and Paris, France and additional manufacturing capability in Frankfurt, Germany.

For more information, please visit http://www.ixaka.com

Connect with us: Twitter: https://twitter.com/ixaka_Ltd; LinkedIn: https://www.linkedin.com/company/ixaka-limited/

About Ixakas multi-cell therapies

Multi-cell therapies (MCT) are derived from natural tissue extracts which are selected for the most active cells, removing components (such as red blood cells and platelets) that potentially reduce the activity of therapeutic cells. Our first MCT is REX-001, which is currently in a multi-site Phase 3 clinical trial for chronic limb-threatening ischemia (CLTI).

Ixakas REX-001 MCT consists of a combination of progenitor cells and immune cells (lymphocytes, monocytes and granulocytes) which are selected and concentrated from a patients own bone marrow and administered directly to the site of occluded blood vessels in the lower leg. Locally administered REX-001 acts to regenerate blood vessels (through both direct and indirect paracrine mechanisms), modulate immune responses, improve blood flow, improve tissue oxygenation, and promote wound healing. These effects lead to a significant improvement in clinical outcomes and quality of life through complete ulcer healing and alleviation of chronic ischemic rest pain.

About Ixakas in vivo gene delivery technology

Ixakas targeted nanoparticle (TNP) therapeutic is a platform which enables therapeutic cells to be targeted and genetic modifications to be performed directly inside the body. The first application is in the generation of chimeric antigen receptor (CAR) T-cell therapies for haematological malignancies. Modifications of the components however allows the technology to target a broad range of therapeutic cells for the treatment of many serious diseases including cancers, genetic disorders, neurological, autoimmune and ocular diseases.

The TNP in vivo gene delivery approach enables targeting of specific cells and expression of the gene of interest directly in the patient. The technology is also targeted and controllable offering potentially improved efficacy and safety. Generation of enhanced therapeutic cells through genetic modification inside the body also enables more standardized manufacturing which is less expensive as it does not require costly dedicated manufacturing sites needed to expand cells before use (as is required for ex vivo cell therapies).

See the original post here:
Ixaka (formerly Rexgenero) Launches as an Integrated Cell and Gene Therapy Company - Business Wire

Taysha Gene Therapies and UT Southwestern Medical Center Launch Innovation Fund to Accelerate Advancement of AAV Gene Therapies for Monogenic Diseases…

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, and UT Southwestern Medical Center (UTSW) today announced the launch of an innovation fund to discover and develop novel gene therapy candidates and next-generation technologies for monogenic diseases of the CNS. This expanded partnership will support UTSWs discovery efforts to facilitate the translation of promising discoveries from bench to clinic. Taysha will have an exclusive option on new programs and intellectual property associated with, and arising from, the research conducted under this agreement.

A team of researchers from the gene therapy program at UT Southwestern will explore novel gene therapy targets in new disease areas and create next-generation gene therapy technology platforms to address some of the current limitations of this modality.

We are excited to expand our alliance with UTSW to accelerate the discovery and development of novel gene therapy candidates and next-generation technologies for patients with monogenic CNS diseases, said RA Session II, President, Founder and CEO of Taysha. We believe that the combination of UTSWs translational research expertise in gene therapy and strong track record of innovation and our experience in drug development and GMP manufacturing will create opportunities to reach more patients with unmet medical needs. Our relationship with the UTSW gene therapy program has produced over 18 novel product candidates, including TSHA-101 in GM2 gangliosidosis and TSHA-118 in CLN1, which are currently in clinical development. We are pleased by the significant progress our partnership has achieved and are excited to build on that foundation and momentum to bring additional compelling innovation to the clinic.

About The University of Texas Southwestern Medical Center

UT Southwestern, one of the premier academic medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. The institutions faculty has received six Nobel Prizes and includes 23 members of the National Academy of Sciences, 17 members of the National Academy of Medicine, and 13 Howard Hughes Medical Institute Investigators. The full-time faculty of more than 2,500 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide care in about 80 specialties to more than 105,000 hospitalized patients, nearly 370,000 emergency room cases, and oversee approximately 3 million outpatient visits a year.

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our teams proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platforman engine for potential new cureswith a goal of dramatically improving patients lives. More information is available at http://www.tayshagtx.com.

Here is the original post:
Taysha Gene Therapies and UT Southwestern Medical Center Launch Innovation Fund to Accelerate Advancement of AAV Gene Therapies for Monogenic Diseases...

Parent Project Muscular Dystrophy Invests $1 Million in Satellos Bioscience to Support New Regenerative Medicine Technology – PRNewswire

HACKENSACK, N.J., Jan. 19, 2021 /PRNewswire/ --Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), today announced a $1 million programmatic investment in Satellos Bioscience Inc. (Satellos) to support the development of a new regenerative medicine for the therapeutic treatment of Duchenne.

Duchenne is the most common fatal genetic disorder diagnosed in childhood, affecting approximately one in 5,000 live male births. Duchenne is caused by a change in the dystrophin gene. In people living with Duchenne, it was discovered by Dr. Michael Rudnicki, the scientific founder of Satellos, that muscle stem cells are severely compromised in their ability to create muscle progenitor cells which repair injured muscle. As a result, people with Duchenne are unable to keep up with the continuous damage to their muscles throughout life.

Satellos's technology is based on this ground-breaking discovery into what controls muscle stem cell differentiation, and the significant impact its dysregulation has on the progressive nature of Duchenne. The company is developing a means to correct this problem through a novel therapeutic approach involving the administration of a small molecule drug, which mobilizes the body's own muscle stem cells, also known as satellite cells, to repair and regenerate muscles.

Such a small molecule drug could be used to treat all people living with Duchenne and furthermore, could be used throughout life to boost the continuous repair and regeneration of skeletal muscle ravaged by this disease, thereby enhancing and extending the lives of people with Duchenne.

"For over 25 years, PPMD has been committed to exploring and supporting every single therapeutic possibility. With this programmatic investment in Satellos, we continue our cutting-edge approach to accelerate finding treatments that have the potential to end Duchenne for every single person impacted by the disease," said Eric Camino, PhD, PPMD's Vice President of Research and Clinical Innovation. "There is compelling proof of concept data showing that the Satellos technology can improve muscle quality and restore function in the mdxmouse model of Duchenne. This investment from PPMD will enable the Satellos team to build on their proof of concept by amplifying their efforts to invent and refine a drug development candidate suitable for testing in humans."

"We are delighted to be working with PPMD and proud to have the therapeutic potential of our novel science recognized by such a leading entity in the fight against Duchenne", said Frank Gleeson, Satellos founder and CEO. "Our profound discoveries into how muscle stem cells repair and regenerate muscle offers a new avenue for addressing a root cause of the progressive debilitation characteristic of Duchenne. Support from PPMD will enable us to accelerate the development of our new treatment approach which offers the promise of helping Duchenne patients of all ages and stages of disease."

To learn more about PPMD's robust Research Strategy, funding initiatives, and strategies for accelerating drug development,click here.

ABOUT PARENT PROJECT MUSCULAR DYSTROPHY:

Duchenneis a fatal genetic disorder that slowly robs people of their muscle strength.Parent Project Muscular Dystrophy (PPMD)fights every single battle necessary to end Duchenne.

We demand optimal care standards and ensure every family has access to expert healthcare providers, cutting edge treatments, and a community of support. We invest deeply in treatments for this generation of Duchenne patients and in research that will benefit future generations. Our advocacy efforts have secured hundreds of millions of dollars in funding and won four FDA approvals.

Everything we doand everything we have done since our founding in 1994helps those with Duchenne live longer, stronger lives. We will not rest until we end Duchenne for every single person affected by the disease. Join our fight against Duchenne atEndDuchenne.org.Follow PPMD onFacebook,Twitter, Instagram, andYouTube.

ABOUT SATELLOS BIOSCIENCE INC.:

Satellos is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in life threatening disorders. Our founding scientist, Dr. Michael Rudnickidiscovered that the dysregulation of stem-cell polarity a process that balances replenishment of stem cells and production of specialized tissue cells, including muscle can lead to the inability of the body to properly repair and regenerate muscle throughout life.

Satellos is initially applying these discoveries to our lead program to develop a new therapeutic treatment which restores muscle regeneration in Duchenne muscular dystrophy, a lethal degenerative disease. Defects in muscle regeneration are also causative in many chronic conditions which we plan to pursue including sarcopenia (muscle wasting with age), cachexia (muscle wasting from chemotherapy or smoking) and various dystrophies. Founded in 2018, Satellos is headquartered in Canada.For more information about Satellos' discovery platform and development programs please visit Satellos.com.

SOURCE Parent Project Muscular Dystrophy (PPMD)

Join the fight. End Duchenne.

Go here to read the rest:
Parent Project Muscular Dystrophy Invests $1 Million in Satellos Bioscience to Support New Regenerative Medicine Technology - PRNewswire

Bone Therapeutics, Rigenerand Ink Cell Therapy Deal – Contract Pharma

Bone Therapeutics, a cell therapy company addressing unmet medical needs in orthopedics and other diseases, and Rigenerand SRL, a biotech company that both develops and manufactures medicinal products for cell therapy applications, primarily for regenerative medicine and oncology, have signed an agreement for a process development partnership.Allogeneic mesenchymal stem cell (MSC) therapies are currently being developed at a fast pace and are evaluated in numerous clinical studies covering diverse therapeutic areas such as bone and cartilage conditions, liver, cardiovascular and autoimmune diseases in which MSCs could have a significant positive effect.Advances in process development to scale up these therapies could have major impacts for both their approval and commercial viability. This will be essential to bring these therapies to market to benefit patients as quickly as possible, said Miguel Forte, chief executive officer, Bone Therapeutics. While Bone Therapeutics is driving on its existing clinical development programs, we have signed a first formal agreement with Rigenerand as a fellow MSC-based organization. This will result in both companies sharing extensive expertise in the process development and manufacturing of MSCs and cell and gene therapy medicinal products. Bone Therapeutics also selected Rigenerand to partner with for their additional experience with wider process development of advanced therapy medicinal products (ATMPs), including the conditioning and editing of MSCs.The scope of collaborations between Bone Therapeutics and Rigenerand aims to focus on different aspects of product and process development for Bone Therapeutics expanding therapeutic portfolio. Rigenerand will contribute to improving the processes involved in the development and manufacture of Bone Therapeutics MSC based allogeneic differentiated cell therapy products as they advance towards patients. The first collaboration between the two organizations will initially focus on augmented professional bone-forming cellscells that are differentiated and programmed for a specific task. There is also potential for Bone Therapeutics to broaden its therapeutic targets and explore new mechanisms of action with potential gene modifications for its therapeutic portfolio.In addition to Rigenerands MSC expertise, Bone Therapeutics also selected Rigenerand as a partner for Rigenerands GMP manufacturing facility. This facility, situated in Modena, Italy, has been designed to host a number of types of development processes for ATMPs. These include somatic, tissue engineered and gene therapy processes. These multiple areas of Rigenerand capabilities enable critical development of new processes and implementation of the gene modification of existing processes. In addition, Rigenerand has built considerable experience in cGMP manufacturing of MSC-based medicinal products, including those that are genetically modified.Process development and manufacturing is a key part of the development for ATMPs internationally. Navigating these therapies through the clinical development phase and into the market requires a carefully considered process development pathway, said Massimo Dominici, scientific founder, Rigenerand, professor of medical oncology, and former president of the International Society for Cell & Gene Therapy (ISCT). This pathway needs to be flexible, as both the market and materials of these therapies continues to evolve alongside an improved clinical efficacy.Giorgio Mari, chief executive officer, Rigenerand, said, Rigenerand will offer considerable input from its experience of MSC-based therapies to enable Bone Therapeutics to keep and further accelerate the pace in development of the product processes of its MSC based allogeneic differentiated cell therapy as they advance towards patients. We will continue to use our MSC expertise in the development of Rigenerands own products, as well as in process development and manufacturing cell and gene therapies for partner organizations across the globe.

See original here:
Bone Therapeutics, Rigenerand Ink Cell Therapy Deal - Contract Pharma

Liquid Biopsy Promising in Children With Vascular Malformations – On the Pulse

Ezra Anpo (right), here with his sister Aria, participated in a research study investigating a liquid biopsy approach to providing a genetic diagnosis in children with lymphatic malformations.

Doctors at Seattle Childrens are investigating whether a simple liquid biopsy containing a small amount of fluid from a patient may someday provide an easier route to a genetic diagnosis in children with vascular or lymphatic malformations.

The work is a collaborative effort led by Dr. James Bennett, a clinical geneticist and co-director of the molecular diagnostic laboratory at Seattle Childrens and Dr. Jonathan Perkins, an otolaryngologist and director of the Seattle Childrens Vascular Anomalies Program. Liquid biopsy offers an alternative to the more invasive surgical biopsies required when a genetic, or molecular diagnosis, is needed to help guide a patients treatment.

We can now provide a specific genetic diagnosis for a lot of vascular malformations, Bennett said. Thats important for families for a variety of reasons with one being its just extremely healing and powerful to know the reason why your child has these differences.

Bennett adds that many of the genetic causes behind vascular malformations are in the same pathways involved in different adult cancers. Several drugs approved for cancer target these pathways by calming down overactive cell growth. A number of these drugs are already being tested in clinical trials for children with vascular malformations, but a genetic diagnosis is needed to determine if a child is a candidate for these studies.

A liquid biopsy offers a fast pass to get a specific molecular diagnosis without necessarily having to do a surgery on a child, Bennett said. If we can convert our research into a clinical grade test, we have the opportunity to potentially make a lot more kids eligible for the clinical trials investigating new drugs to treat vascular malformations.

Dr. James Bennett (left) and Dr. Jonathan Perkins (right) of Seattle Childrens.

Lymphatic malformations occur in about 1 in every 4,000 births when the tubes that carry lymph fluid throughout the body form abnormally. Most often, lymphatic malformations are in the head and neck, sometimes forming large fluid filled cysts. The vessels inside the cysts may shed their DNA into the surrounding fluid.

Bennett was interested in identifying alternative ways to make a genetic diagnosis in patients with vascular malformations without the need for surgery, and Perkins hypothesized that a little fluid taken directly from the cyst could provide enough DNA from the malformation to hunt for any genetic mutations.

When you take a fluid sample from a patient and you spin all the cells in a centrifuge, the cells go to the bottom and you get this layer of liquid on top, Bennett said. It turns out theres tiny little molecules of DNA, called cell-free DNA, that float around in that liquid. Its called cell-free because the DNA is not inside a cell. We can then analyze this cell-free DNA for mutations present in the patients malformation using genetic tests.

A paper published in Genetics in Medicine by Bennett, Perkins and others from Seattle Childrens Center for Clinical and Translational Research and Center for Developmental Biology and Regenerative Medicine used the liquid biopsy approach to identify genetic mutations in the cyst fluid cell-free DNA in patients with lymphatic malformations.

First, they tested the approach using a bank of vascular malformation patient tissue samples stored at Seattle Childrens in which the genetic diagnosis was already known. Liquid biopsy of cyst fluid cell-free DNA identified the previously known mutations in all seven lymphatic malformation samples. Prospective testing of cyst fluid cell-free DNA in lymphatic malformation patients who had never undergone surgery identified a genetic cause in four out of five of those enrolled in the study. The liquid biopsy did not find genetic mutations in the plasma from patients with lymphatic malformations but did find mutations in plasma from blood samples taken from patients with other types of vascular malformations.

This gives us the first proof of principle that we can detect genetic mutations using a liquid biopsy of cyst fluid from children with lymphatic malformations, Bennett said. This is significant because the procedure to draw the fluid from the cyst is much less invasive and complicated than surgically removing the tissue needed in the operating room.

Ezra was born with an extensive lymphatic malformation in his neck. His parents sought out Dr. Perkins for his expertise in treating vascular anomalies such as his.

Today, Ezra Anpo, 2, zooms around the room chasing his older sister. The fact he is living a normal childhood means everything to his parents, Chelsea Gillis and Hideki Anpo.

When Gillis was 20 weeks pregnant with Ezra, an ultrasound showed a concerning lymphatic malformation near his neck. The malformation continued to grow and at 28 weeks pregnant, his parents received a referral to see Perkins.

Ezra has a lymphatic malformation thats more extensive than most, said Perkins. Its location near the back of his tongue means that any significant inflammation could block his airway and send him to the hospital or into surgery.

On January 9, 2019, Ezra was born at the University of Washington Medical Center and was transferred immediately to Seattle Childrens Neonatal Intensive Care Unit (NICU). The team in the NICU stabilized Ezras breathing and supported his feeding while Seattle Childrens vascular anomalies care team determined a longer-term treatment plan.

Given the growing number of options available, Perkins wanted Ezra to undergo genetic testing to confirm his diagnosis and help guide his treatment. However, the standard approach of taking a biopsy from the malformation during a surgery also put Ezra at high risk of damaging his airway. If the airway became compromised, he would need a tracheostomy to breathe.

Ezra with his parents in Seattle Childrens NICU.

There was a lot of concern about doing any type of surgery that could cause an inflammatory reaction, which would most likely result in a tracheotomy, Gillis said. Both dad and I were adamant that we wanted to do everything possible to avoid a tracheostomy.

Perkins told the family about the liquid biopsy approach in development. Since he would only need to draw fluid from the cyst using a needle, it offered a significantly less invasive, and less complicated way to confirm Ezras genetic diagnosis.

The family agreed to move forward with the experimental test. Perkins took the fluid from Ezras cyst during a procedure to place a gastrostomy tube.

Shortly after, the family and Perkins had answers from the liquid biopsy: Ezra had a mutation in a gene called PIK3CA. Starting treatment with an immunosuppressant drug could provide initial benefit until he was old enough to potentially enroll in a clinical trial of a therapy that targets his mutation.

For now, the results of Ezras test are for research use only, though Bennett is hoping to develop a clinically available option in the near future.

Earlier this year, Bennett received a $2.5 million, five-year Research Project Grant (R01) grant from the National Institutes of Health to continue studying the use of cell-free DNA in larger numbers of patients with vascular malformations. Another area Bennett is excited to explore is whether the liquid biopsy could serve as a biomarker for patients receiving medication therapy.

Once a child is on a drug targeted to a specific mutation and youre trying to figure out if the drug is helping or not, you could potentially use this test to look for trends in the mutated DNA over time, he said. If levels of this DNA are trending down, it could indicate a drug is working.

As part of the research study, the liquid biopsy provided a genetic diagnosis for Ezra in a less invasive way than the standard surgical biopsy used to obtain a sample for genetic testing.

A precision diagnostic test developed by Seattle Childrens is already widely used in patient care. It is the only genetic testing panel certified for clinical use with vascular malformations at a childrens hospital.

The Vascular Anomalies Sequencing Panel, or VANseq, tests for mutations in 44 genes known to cause vascular anomalies. Doctors can use results from VANseq to make treatment decisions or help qualify patients for clinical trials. The advanced test currently accepts blood, saliva or tissue specimens obtained from the patient, but Bennett believes their research is on path to add testing with cell-free DNA to the clinical test.

There are labs doing clinical grade testing with cell-free DNA, mostly for cancer, Bennett said. We have more work to do to before the cell-free test for vascular anomalies is ready for clinical use, but Im confident well get there.

Beyond diagnostics, Seattle Childrens has long led advances to improve care for children with vascular anomalies. A collaborative team of physician-scientists work together to bring innovations such as glue embolization and facial mapping to the nearly 2,000 children the program sees each year.

With two clinical trials investigating the use of targeted therapies for vascular malformations already open at Seattle Childrens, Perkins sees an opportunity to move the field forward yet again.

Its completely shifting the paradigm of treatment of vascular malformations from surgery to medical therapy, Perkins said. We can get to the root of whats causing the malformation and using that information, develop new treatments that hopefully will be significantly more effective than what weve had to offer before.

Ezra celebrated his second birthday earlier this month.

The collaborative model embraced by Perkins, Bennett and the vascular anomalies team has helped Ezras parents feel supported through their sons hospitalization and ongoing care.

Im thankful because we took a good path with Ezra, Anpo said. The part I appreciate most is that it was a team effort. We were involved in the decision making and I felt like we got the information we needed from his whole medical team to guide us to the right decision.

Perkins estimates if Ezra had needed a tracheostomy, he would have had a much longer hospital stay upfront and then likely needed several trips to the operating room in his first two years of life. His mother is grateful they were given the option to avoid surgery and get a genetic diagnosis through the research study.

We are very appreciative that Dr. Perkins listened to us and really took our overall goals into account when making decisions about our sons care, she said. Were so fortunate. We havent needed any major surgeries, and Ezra is thriving. Hes fully oral besides his meds, his breathing is great and hes developing normally. Hes so full of life.

Related

Read more:
Liquid Biopsy Promising in Children With Vascular Malformations - On the Pulse

First wave of COVID-19 linked to spike in cardiovascular deaths – Medical News Today

In the United States, cardiovascular deaths that were not directly due to COVID-19 surged early in the pandemic. The postponement of procedures, the extra strain on services, and patients avoidance of hospitals may partly explain the increase.

About one-third of the 225,530 excess deaths in the U.S. during the first months of the pandemic were not directly due to COVID-19, according to a recent study.

Despite this additional death toll, other research showed that the number of people admitted to the hospital with cardiovascular conditions fell sharply in March 2020, coinciding with the rise in COVID-19 cases.

Hospital visits for heart attacks and other cardiac conditions declined markedly during the pandemic, fueling physicians concerns that people with acute conditions may be staying at home due to fear of exposure to COVID-19, says Dr. Rishi K. Wadhera, a cardiologist at the Beth Israel Deaconess Medical Center (BIDMC) in Boston, MA.

Stay informed with live updates on the current COVID-19 outbreak and visit our coronavirus hub for more advice on prevention and treatment.

New research adds to these concerns. According to the study, which Dr. Wadhera led, cardiovascular deaths unrelated to COVID-19 increased in New York State, New Jersey, Michigan, and Illinois during the first wave of the pandemic relative to cardiovascular deaths in the same period of 2019.

In New York City, which the first wave hit particularly hard, deaths from ischemic heart disease (which results from narrowed cardiac arteries) increased by 139%, and deaths from hypertensive disease (due to high blood pressure) increased by 164%.

These data are particularly relevant today, as we find ourselves in the midst of a surge in COVID-19 cases that looks to be exceeding what we experienced last spring, says senior author Robert Yeh, director of the Smith Center for Outcomes Research at BIDMC.

Ensuring that patients with cardiovascular disease continue to receive necessary care during our public health response to the pandemic will be of paramount importance, he adds.

The analysis appears in the Journal of the American College of Cardiology.

The researchers drew on data from the National Center for Health Statistics to compare cardiovascular death rates at the start of the pandemic (from March 18, 2020, to June 2, 2020) with those during the preceding 11 weeks.

To account for seasonal trends, they then compared this figure with the change in cardiovascular death rates over the same period in 2019.

Overall, the rate of deaths due to ischemic heart disease increased by 11% over this period in 2020 compared with the previous year. The rate of deaths resulting from hypertensive disease increased by 17%.

There was no increase in death rates from heart failure, cerebrovascular disease (such as strokes), or other circulatory diseases.

The surge in cardiac death rates was concentrated in New York State, New Jersey, Michigan, and Illinois, which were among the states most affected by COVID-19 during the first wave of the pandemic.

One exception was Massachusetts, which did not see increases in cardiac death rates, despite being an epicenter of COVID-19 cases.

The researchers speculate that people who experienced acute cardiac symptoms may have avoided medical care because they were worried about contracting the virus in the hospital. As a result, more people died at home without receiving the necessary treatment.

The study authors note that the incidence of cardiac arrests in the community has increased during the pandemic.

One study suggests that slower emergency service response times and an increased reluctance among bystanders to perform CPR contributed to reduced survival rates after cardiac arrest.

The authors of the current study list several factors relating to the healthcare system that may have contributed to the surge in cardiac deaths, including:

Increased stress levels among patients in the midst of the crisis may also have played an important role, they write.

The authors conclude:

As COVID-19 cases surge in different regions of the U.S., public health officials and policymakers should improve public health messaging to encourage patients with acute conditions to seek medical care and expand healthcare system resources to mitigate the indirect effects of the pandemic.

They note that their study was based on provisional data from the Centers for Disease Control and Prevention (CDC), which may have been incomplete due to reporting delays.

In addition, some deaths may have been misclassified as cardiovascular deaths when COVID-19 was the actual underlying cause. To support this statement, the authors cite research suggesting that some patients with COVID-19 develop cardiac complications.

For live updates on the latest developments regarding the novel coronavirus and COVID-19, click here.

See the article here:
First wave of COVID-19 linked to spike in cardiovascular deaths - Medical News Today

Study On Rabbit Brain Reveals Genetic Markers Of Domestication – Texas A&M University Today

Tolerance of humans and tameness are noted traits differentiating domestic and wild rabbits.

Getty Images

An international team of researchers led by Leif Andersson, a professor at the Texas A&M University College of Veterinary Medicine & Biomedical Sciences (CVMBS), has found changes in gene expression patterns across the brain between wild and domestic rabbits, which likely contributed to the evolution of tameness during domestication.

By demonstrating that domestic animals acquired tolerance toward humans through regulatory changes of certain genes, researchers are able to better understand the link between genetic changes and the mechanisms of evolution in rabbits and, at a larger scale, of plants and animals in general. The research builds off Anderssons previous work demonstrating a link between rabbit domestication and brain structure.

The European rabbit is one of the most recently domesticated animals, exhibiting distinct morphological, physiological and behavioral differences from their wild counterparts. Tolerance of humans and tameness are noted traits differentiating the domestic and wild rabbits.

Domestication is often associated with the rapid development of such traits in a rather short evolutionary time period. As such, domestication has long been a major topic in evolutionary biology, as it allows researchers to study the mechanisms of evolution on a more manageable time scale.

In the study, published in Genome Biology and Evolution, the researchers compared gene expression patterns in four brain regions between newborns of wild and domestic rabbits. They detected hundreds of genes differentially expressed between the two.

It is important to notice that the drastic changes in behavior between domestic animals and their wild ancestors are associated with changes in how genes are expressed during the development of the brain, Andersson said. The domestication of plants and animals is one of the most important developments during human history. In this study, we shed light on how this process has altered brain function in domestic animals and made them tamer.

One significant finding was that genes involved in dopamine signaling, a chemical involved in fear responses, were expressed at higher rates in the amygdala, or area of the brain associated with memory, decision-making, and emotional responses, of the domestic rabbit. Notably, the amygdala is known as the part of the brain driving the fight or flight response, which would play a part in determining whether a wild animal flees in the company of humans or a tame animal tolerates human presence.

Researchers also found that genes associated with ciliary function were consistently downregulated in the hippocampus, an area of the brain associated with learning and memory, of domestic rabbits. Cilia cells are tiny hair-like structures that aid in the circulation of cerebrospinal fluid.

The flow of this fluid contributes to the transmission of molecular signals across the brain. Since these ciliary genes are important for brain development, the researchers hypothesized that these changes contribute to the evolution of tameness.

We were really surprised by the consistent changes we observed that several genes involved in dopamine signaling were consistently unregulated in the domestic brain, and that many genes with associated with ciliary function was consistently downregulated, Andersson said.

Read the original post:
Study On Rabbit Brain Reveals Genetic Markers Of Domestication - Texas A&M University Today

2021 Research Grant Recipients Announced by the VHL Alliance – PRNewswire

BOSTON, Jan. 19, 2021 /PRNewswire/ --The VHL Alliance (VHLA) today announced the 2021 recipients of the VHLA Competitive Research Grant Program. This year, three grantees were chosen. Scientists are increasingly aware that curing von Hippel-Lindau disease, a genetic form of cancer is a key step to curing cancer, leading to a significant increase in the quality of research grant applicants in the program year after year.

Over 20 top VHLA researchers from across the US, Canada, and Europe were involved in reviewing and selecting those projects which have the greatest potential to make advances toward Curing Cancer through VHL. For the second year in a row, responding to the increase in quality applications, the VHLA Board of Directors voted to expand the annual budget for research.

This year's grant recipients were:

Dr. Tirosh proposes to investigate the microenvironment of pancreatic neuroendocrine cancers using computational biology. Dr. Jonasch will test in the laboratory whether VHL-associated kidney cancers respond to a new class of medication that exploits DNA stress. Finally, Dr. Zagzag will test whether a change in a specific protein expressed in hemangioblastomas can determine their growth rate.

"The VHL Alliance is proud to fund basic scientific and translational research of the highest quality, poised to shed light into the mechanisms of VHL tumors and lead to discovery of new ways to prevent and treat VHL patient tumors,"said Othon Iliopoulos, MD, PHD, board member and chair of the VHLA Research Council, and Clinical Director, Von-Hippel Lindau Disease/Familial Renal Cell Cancer Program, Associate Professor of Medicine, Center for Cancer Research, Massachusetts General Hospital, Boston, MA.

"Once again, the VHL Alliance Research Council was impressed with the range and quality of grant applications received. We have seen a growing interest among researchers in solving the mystery of the VHL gene - an important key to unlocking the mechanisms of tumor growth and ultimately, cancer," said Chandra Clark, Executive Director of the VHL Alliance. "VHL disease affects 1 in 36,000 people around the world regardless of gender, race, socioeconomic, or geographic circumstances, and finding a cure will benefit thousands of cancer patients."

For more information about the VHL Alliance or the 2021 VHLA Competitive Research Grant Program, please visit vhl.org.

About VHLVHL or von Hippel-Lindau disease is a genetic form of cancer. VHL patients battle a series of tumors throughout their lives. The VHL gene controls the major feeding pipeline of every tumor. Curing VHL is one step closer to curing many other forms of cancer. There are currently 8 drugs being used to effectively treat cancer, mainly kidney cancers, which are direct results of VHL research.

About the VHL AllianceThe VHL Alliance (VHLA) is the preeminent resource and clearinghouse for those affected by von Hippel-Lindau disease, including patients, caregivers, researchers, and the medical community. VHLA is a 501(c)(3) non-profit organization founded in 1993, which is dedicated to research, education, and support to improve awareness, diagnosis, treatment, and quality of life for those affected by VHL. VHLA is the leading funder of VHL research, funding over $2.5 million in grants to support studies designed to find a cure. The VHL Alliance's vision is Curing Cancer through VHL.

About the VHLA Competitive Research Grant ProgramThe VHLA's Competitive Research Grant program awards two types of Grants: Pilot Grants ($25,000 for one year), designed to help researchers prepare the basic modelling required to then pursue larger grants; and Research Grants ($150,000 over three years),designed to obtain sufficient data to apply for government funded resources. Previous grants have contributed to our understanding of how the VHLgene contributes to the tumorigenesis including how to overcome the body signaling and response to what it perceives as a hypoxic (low oxygen) environment.

Contact: Heidi Leone, Director of AdvancementVHL Alliance617.277.5667 x 4[emailprotected]

SOURCE VHL Alliance

Excerpt from:
2021 Research Grant Recipients Announced by the VHL Alliance - PRNewswire

ARUP Sequencing Specimens Positive for SARS-CoV-2 to Detect the UK Variant and Other Possible Strains of the Virus – PRNewswire

SALT LAKE CITY, Jan. 19, 2021 /PRNewswire/ --ARUP Laboratories, a major provider of COVID-19 molecular diagnostic testing in Utah and nationwide, today announced that it is sequencing variants of SARS-CoV-2 in specimens positive for COVID-19 to enable detection of the more contagious "United Kingdom (UK) variant" of the virus.

ARUP's announcement came after the Utah Department of Health (UDOH) on Jan. 15, 2021, said that a Salt Lake County man had been found to have the so-called "UK," or B.1.1.7 variant, which so far has been detected in 20 states. The first known case of the variant in Utah, it was identified by the UDOH Public Health Laboratory, which since early in the pandemic has been sequencing a percentage of specimens positive for COVID-19 as part of an effort in which ARUP is collaborating.

Independently, ARUP has begun sequencing all specimens identified as positive for SARS-CoV-2 through molecular testing on one of three platforms it uses to test for the virus. ARUP, which offers a full menu of COVID-19 testing for hospital and health system clients nationwide, does not release sequencing variant information for individual patients. Rather, sequencing is performed for epidemiologic purposes and to monitor and, if necessary, improve the performance of the tests used to diagnose COVID-19.

"Our sequencing research seeks to characterize not just the UK variant, but other circulating strains of SARS-CoV-2, so that we may continue to develop accurate tests for the virus," said Adam Barker, PhD, director of the ARUP Institute for Clinical and Experimental Pathology.

The UK variant is known to contain a mutation of the spike protein, or S gene, which one of ARUP's tests uses as a target for SARS-CoV-2 identification, along with two other genes. Read more about ARUP's tests and about how ARUP is sequencing variants here.

Genetic sequencing of SARS-CoV-2 variants for research and epidemiologic purposes is a good example of ARUP's unique ability to offer vital testing while also contributing to scientific advancement, thanks to its affiliation with the University of Utah (U of U). ARUP is a not-for-profit enterprise of the U of U School of Medicine and its Department of Pathology, and Barker and all ARUP medical directors are also U of U faculty members.

"Our work to help advance laboratory medicine and improve patient care is at the heart of what we do at ARUP," said CEO Sherrie L. Perkins, MD, PhD. "As this public health crisis persists, our commitment is stronger than ever."

More information about ARUP's COVID-19 test menu and about other COVID-19-related research in which ARUP is involved is available at aruplab.com.

About ARUP Laboratories

Founded in 1984, ARUP Laboratories is a leading national reference laboratory and a nonprofit enterprise of the University of Utah and its Department of Pathology. ARUP offers more than 3,000 tests and test combinations, ranging from routine screening tests to esoteric molecular and genetic assays. ARUP serves clients across the United States, including many of the nation's top university teaching hospitals and children's hospitals, as well as multihospital groups, major commercial laboratories, group purchasing organizations, military and other government facilities, and major clinics. In addition, ARUP is a worldwide leader in innovative laboratory research and development, led by the efforts of the ARUP Institute for Clinical and Experimental Pathology. ARUP is ISO 15189 CAP accredited.

Media ContactARUP: Lisa Carricaburu,[emailprotected],801-541-5041

SOURCE ARUP Laboratories

http://www.aruplab.com

Visit link:
ARUP Sequencing Specimens Positive for SARS-CoV-2 to Detect the UK Variant and Other Possible Strains of the Virus - PRNewswire

BCH-BB694 Gene Therapy Safely Treating Severe SCD Patients in… – Sickle Cell Anemia News

BCH-BB694 an experimental gene therapy targeting the BCL11A gene safely increased the levels of fetal hemoglobin and prevented disease-associated complications in six people with severe sickle cell disease (SCD), according to interim data from a Phase 1 clinical trial.

These findings further support the feasibility and therapeutic value of approaches targeting BCL11A,which is involved in the suppression of fetal hemoglobin in adult red blood cells.

Trial findings were reported in the study, Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease, published in The New England Journal of Medicine.

BCH-BB694, developed by a team of researchers at Boston Childrens Hospital led by David Williams, MD, uses a modified and harmless virus to promote the production of fetal hemoglobin in blood precursor cells (hematopoietic stem cells)collected from a patient.

The virus was created in collaboration with Bluebird Bio, and delivers a genetic sequence with the instructions to produce a microRNA that suppresses BCL11As activity in red blood cells.

MicroRNAs are small RNA molecules that target a specific genes messenger RNA the genetic blueprint derived from DNA and used as a template for protein production to prevent generation of that protein.

The modified cells are re-introduced to the patient in the form of astem cell transplant, following myeloablativechemotherapy to kill cells in the bone marrow, thereby lowering the number of blood-forming cells. This way, the stem cell transplant will have a better chances of rebuilding a healthy bone marrow.

Of note, fetal hemoglobin is a form of hemoglobin produced during fetal development that is more effective at transporting oxygen than its adult counterpart.By increasing the levels of fetal hemoglobin, BCH-BB694 is expected to lower the frequency of SCD complications, such as vaso-occlusive crises (VOCs) and acute chest syndrome.

Based on positive data from preclinical studies, Williams is sponsoring a two-year, pilot Phase 1 trial (NCT03282656) to evaluate the feasibility, safety, and preliminary effectiveness of a single administration of patients own blood precursor cells modified with BCH-BB694 to people with severe SCD.

Patient recruitment at Boston Childrens Hospital and UCLA Mattel Childrens Hospital in Los Angeles may still be ongoing; more information can be found here. Those who finish two years of follow-up may choose to enter a 13-year long-term follow-up study.

Six of the nine enrolled patients asof October 2020 had at least six months of follow-up data, and were included in the interim analysis. Their age at enrollment ranged from 7 to 25, and they were followed for a median of 18 months (range, seven to 29 months) after treatment.

Results showed that BCH-BB694 treatment was generally safe, with most adverse events being consistent with known effects of myeloablative chemotherapy, and with no reports of severe or life-threatening side effects.

The gene therapy led to a robust and sustained increase in fetal hemoglobin levels, accounting for a median of 30.5% of all hemoglobin levels, and being detected in a median of 70.8% of red blood cells. Mean levels of fetal hemoglobin per red blood cell were also uniformly high.

Based on these laboratory findings, we predict that the patients in this study will have protection from sickling to prevent or significantly ameliorate both acute and chronic complications of sickle cell disease, the researchers wrote.

Notably, all patients remained free from VOCs, acute chest syndrome, and strokes since the treatment was given. Other SCD complications, such as priapism (prolonged, often painful erection), were also reduced.

BCH-BB694s use also prevented a need for blood transfusions in two patients who had been receiving them regularly to avoid a stroke. One patient with a rare blood vessel disorder continued to receive predefined blood transfusions due to a potentially higher risk of stroke, but on a less frequent basis than before treatment.

The initial results of this trial provide validation that BCL11A can be targeted to lead to successful [fetal hemoglobin] induction in humans, the researchers wrote.

Additional follow-up data will help determine BCH-BB69s long-term beneficial effects, they noted.

This type of microRNA-based gene therapy approach has potential implications for other diseases that could benefit from downregulation of gene expression rather than addition of a gene, the team wrote.

The study was supported by a grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health.

A separate Phase 1/2 trial with a different approach in targeting theBCL11A gene also recently released promising findingsinpeople with severe SCD. The therapy being investigated here,CTX001, uses the CRISPR-Cas9 gene editing tool to inactivateBCL11Ain patients blood cell precursors.

Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.

Total Posts: 2

Ins holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Cincias e Tecnologias and Instituto Gulbenkian de Cincia.Ins currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.

Read more here:
BCH-BB694 Gene Therapy Safely Treating Severe SCD Patients in... - Sickle Cell Anemia News

Science News Roundup: Chinese scientists develop gene therapy which could delay ageing; China’s retrieved lunar samples weigh less than targeted and…

Following is a summary of current science news briefs.

Chinese scientists develop gene therapy which could delay ageing

Scientists in Beijing have developed a new gene therapy which can reverse some of the effects of ageing in mice and extend their lifespans, findings which may one day contribute to similar treatment for humans. The method, detailed in a paper in the Science Translational Medicine journal earlier this month, involves inactivating a gene called kat7 which the scientists found to be a key contributor to cellular ageing.

China's retrieved lunar samples weigh less than targeted

Lunar rocks retrieved by a historic Chinese mission to the moon weighed less than initially targeted, but China is still willing to study the samples with foreign scientists, the mission's spokesman said on Monday. China became the third country ever to secure lunar samples when its unmanned Chang'e-5 probe, named after the mythical moon goddess, brought back 1.731 kg (3.8 lb) of samples last month, falling short of the 2 kg (4.4 lb) planned.

Branson's Virgin Orbit reaches space with key mid-air rocket launch

Billionaire Richard Branson's Virgin Orbit reached space for the first time on Sunday with a successful test of its air-launched rocket, delivering ten NASA satellites to orbit and achieving a key milestone after aborting the rocket's first test launch last year. The Long Beach, California-based company's LauncherOne rocket was dropped mid-air from the underside of a modified Boeing 747 nicknamed Cosmic Girl some 35,000 feet over the Pacific at 11:39 a.m. PT before lighting its NewtonThree engine to boost itself out of Earth's atmosphere, demonstrating its first successful trek to space.

(With inputs from agencies.)

Advertisement

googletag.cmd.push(function(){googletag.pubads().display('/42115163/IP_devdiscourse.com_728x90_Resp_Both_BTF', [728,90],'div-gpt-ad-1583931674-61');});" + "ipt>

Read the original:
Science News Roundup: Chinese scientists develop gene therapy which could delay ageing; China's retrieved lunar samples weigh less than targeted and...

‘This Time We Got Lucky’: Virus Variants Reveal Gaps in Tracking – Bloomberg Law

New Covid-19 variants that appear to spread easier than the original strain are sparking concerns that the U.S. system for tracking the virus isnt keeping pace with mutations.

Some scientists say that even though testing works now, health officials need to be better prepared for variants down the road or risk not being able to properly detect the SARS-Cov-2 virus. Theyre calling on the Biden administration to invest more in genomic sequencing, a process that involves collecting the DNA blueprint of an organism.

A new mutation that can hide from a common testing procedure, like the variant that surfaced in the U.K. doesalbeit not significantlymarks a serious tremor before a quake, Fyodor Urnov, a professor in the University of California, Berkeleys Molecular and Cell Biology Department, said. While the variant does hide from one part of the test, most tests use multiple procedures to look for different parts of the SARS-Cov-2 virus, which for now negates the variants ability to avoid detection.

But without a national sequencing effort, the U.S. leaves itself vulnerable to more serious mutations down the line. Not just of SARS-Cov-2, but of any virus.

Sequencing Covid-19 variants is a piecemeal process in the U.S., typically happening in academic institutions or local labs. Some labs are forwarding suspected variant samples to the Centers for Disease Control and Prevention for sequencing. The CDC says its working to expand its ability to track Covid-19 and new variants.

This is a preview of what will be a recurrent problem, Urnov said. The United States of America has to have a federally supported effort to sequence a lot more virus, collect the data in a national database, and make those data available to all who work on molecular test development.

Urnov equates virus mutations to an outlaw changing their appearance and requiring law enforcement officials to update the sketch on their Most Wanted poster.

In this case, the poster is a molecular test. From a virus standpoint, the way to create the sketch is through genomic sequencing. Thats how scientists detect when a virus has mutated.

Right now, it doesnt appear the mutation seriously impacts Covid-19 tests used in the U.S. The Food and Drug Administration warned this month that three tests may be impacted by genetic variants of the virus, but that the impact does not appear to be significant. Covid-19 vaccines will still work too, doctors say.

But theres no way of knowing exactly what will come down the variant pipeline, and some scientists want to be better prepared so the nation isnt caught flat-footed.

This time, we got lucky, Urnov said.

The mutation that was originally detected in the U.K. is found on the viruss spike gene, Kimberly Hanson, a physician and professor at the University of Utah School of Medicine, said on a Covid-19 testing panel in early January.

Many tests that do target that gene, like a widely-used test by Thermo Fisher Scientific, typically also target two other parts of the SARS-Cov-2 virus.

Thermo Fishers test has three gene targets, and scientists only need to hit two out of three targets to determine a test is positive and that person has Covid-19, Hanson said. So even though one testing procedure doesnt pick up the new variant, there are two others that do and act as a safety net.

Antigen tests, or rapid tests, typically target something besides the spike protein, so the vast majority of our tests should be in good shape, Angela Caliendo, a physician and professor at Alpert Medical School at Brown University, said. She spoke at the Infectious Diseases Society of America panel with Hanson.

Eric Blank, the chief program officer for the Association of Public Health Laboratories, doesnt expect major Covid-19 variants to knock the U.S. testing strategy off kilter.

He said current tests will likely still be able to detect future variants, but it remains to be seen how much the virus will mutate.

We expect well see more and more of this over time and itll be a more prevalent thing as time goes on, Blank said of virus mutations. From a public health standpoint, that means we have got to get better about getting vaccines in arms.

The incoming administration says it supports a nationwide testing effort that includes genomic sequencing. Part of the president-elects pandemic strategy is to build better preparedness, according to his pandemic response outline released Jan. 14.

Biden wants to use $11 billion for a variety of pandemic preparedness efforts, including global efforts to build the capacity required to fight COVID-19, its variants, and emerging biological threats.

Scientists hope that means that going forward, the U.S. will see a more robust, nationwide sequencing system than the current piecemeal approach.

The new administration is perfectly positioned to have might of federal government to support the integration of the might of American science, Urnov said.

See the article here:
'This Time We Got Lucky': Virus Variants Reveal Gaps in Tracking - Bloomberg Law

SwanBio Therapeutics Appoints Alison Lawton to Board of Directors – BioSpace

Alison brings significant experience in guiding companies through all stages of drug development and ultimately to commercialization, which are key areas of expertise that will benefit us as we advance toward becoming a clinical-stage gene therapy company, said Tom Anderson, Chief Executive Officer of SwanBio. We are honored to add Alison to our Board of Directors, to support our goal of bringing life-changing treatments to people living with devastating neurological conditions.

I am delighted to join the team at SwanBio at this inflection point in their development as they progress their gene therapy product candidates for patients with neurological diseases, said Ms. Lawton. I look forward to working with the SwanBio team as they advance their programs into the clinic and expand on their platform to help the many patients who remain in need of new treatment options.

Ms. Lawton has more than 30 years of experience in the biopharma industry, most recently serving as the Chief Executive Officer, President and Member of the Board of Directors of Kaleido Biosciences from 2017 to 2020. Prior to joining Kaleido, she was Chief Operating Officer at Aura Biosciences, and previously held the same role at X4 Pharmaceuticals and OvaScience. Ms. Lawton spent more than 20 years at Genzyme Corporation and subsequently at Sanofi, following its acquisition of Genzyme. She served as Senior Vice President and General Manager of Sanofi Biosurgery, a $750 million business that included surgical, orthopedics, cell therapy and regenerative medicine franchises. Earlier, as SVP of Global Market Access for Genzyme, Ms. Lawton led global functional organizations, including regulatory affairs, quality systems, public policy, health outcomes and strategic pricing, product safety and risk management. Additionally, Ms. Lawton worked for seven years at Warner-Lambert/Parke-Davis in the U.K. She previously served two terms as the industry representative on the Food & Drug Administrations Cell & Gene Therapy Advisory Committee and as Chairman of the Board of the Regulatory Affairs Professional Society (RAPS). She is currently an independent Director of ProQR Therapeutics, X4 Pharmaceuticals, Aeglea Biotherapeutics and Magenta Therapeutics. Ms. Lawton earned her Bachelor of Science degree in Pharmacology from Kings College London.

About SwanBio Therapeutics

SwanBio Therapeutics is a gene therapy company that aims to bring life-changing treatments to people with devastating, genetically defined neurological conditions. SwanBio is advancing a pipeline of AAV-based gene therapies, designed to be delivered intrathecally, that can address targets within both the central and peripheral nervous systems. This approach has the potential to be applied broadly across three disease classifications spastic paraplegias, monogenic neuropathies and polygenic neuropathies. SwanBios lead program is being advanced toward clinical development for the treatment of adrenomyeloneuropathy (AMN). For more information, visit SwanBioTx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210119005014/en/

Here is the original post:
SwanBio Therapeutics Appoints Alison Lawton to Board of Directors - BioSpace

Kite Taps Industry Vet to Lead Cell Therapy R&D – BioSpace

AaronP/Bauer-Griffin/GC Images

Kite Pharma has tapped immunotherapy expert Francesco Marincola, a former National Institutes of Health investigator, to helm the companys cell therapy research.

Marincola will be in charge of Kites research organization across hematological malignancies and solid tumors. Kite, a Gilead Sciences company, said Marincola will assume his new responsibilities on Feb. 1.

Marincola joins Kite from his most recent role as president and chief scientific officer of California-based Refuge Biotechnologies, where he led research into that companys cell therapy programs developed with Refuge's receptor-dCas platform. Refuges pipeline is led by RB-1916, a CAR-T cell therapy designed to inhibit the expression of the PD-1 gene, with a potential initial application in diffused large B-cell lymphoma.

Kite is certainly no stranger to CAR-T. Kite is focused on chimeric antigen receptor and T cell receptor engineered cell therapies. In 2017, the U.S. Food and Drug Administration approvedYescarta, the second CAR-T treatment in the United States. The approval came two months after Kite wasacquired by Gilead for $12 billion. Following the approval of Yescarta, Kite dove into cell therapy research.

In 2018, Kite forged a cell therapy-focused partnership with the National Cancer Institute to develop adoptive cell therapies targeting patient-specific tumor neoantigens, which are mutations found on the surface of cancer cells that are unique to each person and tumor. To support its continued research into cell therapies, Kite also scaled up its manufacturing efforts to support CAR-T development in the U.S. and Europe.

Earlier this month, Kite and Oxford BioTherapeutics entered into a research collaboration to evaluate five novel targets for a number of hematologic and solid tumor indications.

Kite Chief Executive Officer Christi Shaw said Marincolas expertise in cell therapy will enable the company to discover and advance new life-saving therapies for patients in need. CAR-T therapy has proven to be successful in some hematological cancers and now researchers are scrambling to aim the potent anti-cancer therapy at solid tumors. Challenges in this area remain, and Marincola is expected to use his own expertise to push this research forward.

Francos proven track record in oncology and robust research experience that spans the NIH to industry will be critical to the targeting and acceleration of our research efforts in CAR T and beyond, Shaw said in a statement.

It is an honor to bring my experience to an industry-leading team that is working to make cell therapies with curative intent available to patients, Marincola said. I look forward to helping build and diversify our research efforts in support of this mission.

In addition to his experience at Refuge, Marincola spent 23 years at the NIH, where he was tenured senior investigator in cancer immunotherapy and biomarker research. During his time at NIH, he spent 15 years as the Chief of the Infectious Disease and Immunogenetics Section at the NIH Clinical Center. Over the course of his career, Marincola also served as a distinguished research fellow in immune oncology discovery at AbbVie and as Chief Research Officer at Sidra Research in Doha, Qatar.

Marincola also served as president of the Society for Immunotherapy of Cancer and currently serves as Editor-in-Chief for several prominent peer-reviewed publications, includingJournal of Translational Medicine,Translational Medicine CommunicationsandImmunotherapy.

Most Read Today

Continue reading here:
Kite Taps Industry Vet to Lead Cell Therapy R&D - BioSpace

Embracing the Charm of Uncertainty in Lung Cancer Research – OncLive

In the dark days of World War II, a 12-year-old boy dodged the Japanese soldiers who occupied his neighborhood in Hong Kong, slipping around corners and into alleys to sell cans of kerosene hed converted from diesel oil to support his widowed mother.

When the occupation was over, he learned English in night school and rented a typewriter so he could make money exporting cheap toys to the West. Eventually, his import-export venture did well enough that he could afford to buy the typewriter outright.

Six decades later, his son, internationally recognized oncologist and investigator Tony S.K. Mok, MD, keeps that same typewriter in his office. Mok calls it his daily reminder to follow his fathers example of entrepreneurship and diligence.

Moks groundbreaking research into treatment options for lung cancer subtypes that are driven by genetic mutations is credited with producing a paradigm shift in fighting the worlds deadliest malignancy.

One look at his resume hints at a curiosity that compels him to seek out experiences not in the average oncologists day: Hes not just a world-renowned cancer investigator and clinician, but hes also the host of several seasons of televised food shows, and hes written a news-paper column for the past 14 years.

His face is so familiar in Hong Kong that an elderly patient, meeting him for the first time, assumed he was just an actor. Are you a real doctor? she asked skeptically, Mok, 60, recounted with laughter. How does he make time for it all?

When an opportunity comes along, 2 things come to my mind: Am I going to like it? And am I going to make a positive contribution to the community? If the answer to both questions is Yes, I find the time, he said.

He was born Shu Kam Mok. When his parents enrolled him in an English-speaking secondary school, the school insisted he take a Christian name. A tutor picked Tony and the name continued to make sense for the next chapter of his life, when his parents sent him to college in Canada at age 16. He received his fellowship training in medical oncology at Princess Margaret Cancer Centre in Toronto, Ontario, having chosen oncology because it seemed to be a field on the cusp of major new developments.

In 1995, he took a tour of the Prince of Wales Hospital, the main teaching hospital of the Chinese University of Hong Kong. At the end of the tour, the head of oncology surprised him with a job offer.

Hong Kong was starting to experience a brain drain of physicians worried about the impending transfer of the British colony to China. Moks credentials as a seasoned oncologist who spoke Chinese made him an attractive candidate, despite his lack of research experience.

Accepting the offer would mean giving up his comfortable life in Canada and taking a big financial hit. On the other hand, hed get to work with Chinese researchers and he was enchanted by the charm of uncertainty. Staying in Toronto meant his life would follow the very predictable path of a suburban physician.

He took the plunge and accepted the offer. He was 36, older than most of his peers, he didnt have a single publication to his name.

Mok noticed that few investigators in Asia were looking lung cancer. The lethality of the disease was discouraging, and its mysteries seemed impenetrable. Where others saw a brick wall, however, Mok saw opportunity.

One of the reasons to go into a field where little is known is because that is exactly the field where youll learn more and create more, he said. I thought, This is a great area where there is going to be great progress.

His early research tackled a grab bag of topics, including pancreatic, colon, and lung cancers, as he tried to catch up with his colleagues. Much of his research has focused on the role of the EGFR gene mutation in nonsmall cell lung cancer (NSCLC). Mok was the lead researcher for the pivotal phase 3 IPASS trial. Investigators randomly assigned 1217 previously untreated patients with advanced lung cancer in East Asia to gefitinib (Iressa) or carboplatin plus paclitaxel.

For patients with the EGFR gene mutation, gefitinib was clearly superior to standard chemotherapy; for patients without the mutation, chemotherapy was superior.

The data, published in the New England Journal of Medicine in September 2009, remade the world of lung cancer treatment and remains 1 of the most cited publications in the field. Based on that data, physicians would test patients with newly diagnosed lung cancer for genetic mutations before choosing a treatment. Lung cancer, so slow to relinquish its secrets, had entered the age of personalized medicine.

While Mok is accessible and friendly by natureand funny, as wellcolleagues say that beneath that convivial exterior is a serious intellect. His presentations at professional conferences are known for delivering not just the latest developments in research, but for put-ting that research into a broader context that every attendee can grasp, even those outside the immediate field of lung cancer.

Hes also a wine connoisseur and foodie who makes it a point to know the best restaurants in every major city. At the American Society of Clinical Oncology (ASCO) Annual Meeting, Mok traditionally arranges a big dinner with friends where shop talk is discouraged.

All his activitiesthe university teaching, the columns in the Hong Kong Economic Times, his work in the clinic, and his researchmake for a very full plate. He wouldnt have it any other way, explaining that being busy fits into his philosophy of life.

The way I see life, the way I define a happy life, is this: At the end of the day, how many happy moments have I collected? So if I collect enough moments, I can call this a happy life, Mok said.

Read more from the original source:
Embracing the Charm of Uncertainty in Lung Cancer Research - OncLive